Underreported threat of multidrug-resistant tuberculosis in Africa

被引:44
作者
Ben Amor, Yanis [1 ]
Nemser, Benneft [1 ]
Singh, Angad [1 ]
Sankin, Alyssa [1 ]
Schluger, Neil [1 ]
机构
[1] Columbia Univ, Earth Inst, New York, NY 10025 USA
基金
美国国家卫生研究院;
关键词
D O I
10.3201/eid1409.061524
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multidrug-resistant tuberculosis (MDR TB) in Africa may be more prevalent than previously appreciated. Factors leading to development of drug resistance need to be understood to develop appropriate control strategies for national programs. We gathered estimates of MDR TB rates for 39 of 46 countries in Africa. The relationship between MDR TB rates and independent factors was analyzed by using correlation and linear regression models. Our findings indicate that drug resistance surveys in Africa are critically needed. MDR TB rates must be assessed in countries without these surveys. In countries that have conducted a drug resistance survey, a new survey will determine evolution of drug resistance rates. We found no correlation between high MDR rates and TB incidence, HIV/TB co-infection rates, or year of introduction of rifampin. Results show that the retreatment failure rate was the most predictive indicator for MDR TB. Current category II drug regimens may increase MDR TB.
引用
收藏
页码:1345 / 1352
页数:8
相关论文
共 41 条
[1]  
Abate G, 2002, ETHIOPIAN MED J, V40, P79
[2]  
Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
[3]   Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection [J].
Bruchfeld, J ;
Aderaye, G ;
Palme, IB ;
Bjorvatn, B ;
Ghebremichael, S ;
Hoffner, S ;
Lindquist, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) :1636-1643
[4]   Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis [J].
Burman, W ;
Benator, D ;
Vernon, A ;
Khan, A ;
Jones, B ;
Silva, C ;
Lahart, C ;
Weis, S ;
King, B ;
Mangura, B ;
Weiner, M ;
El-Sadr, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (03) :350-356
[5]  
Davies GR, 1999, INT J TUBERC LUNG D, V3, P799
[6]  
Demissie M, 2001, SCAND J INFECT DIS, V33, P914, DOI 10.1080/00365540110076822
[7]   Molecular characterization and drug resistance testing of Mycobacterium tuberculosis isolates from Chad [J].
Diguimbaye, C ;
Hilty, M ;
Ngandolo, R ;
Mahamat, HH ;
Pfyffer, GE ;
Baggi, F ;
Tanner, M ;
Schelling, E ;
Zinsstag, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (04) :1575-1577
[8]   Can DOTS control multidrug-resistant tuberculosis? [J].
Espinal, MA ;
Dye, C .
LANCET, 2005, 365 (9466) :1206-1209
[9]   Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa [J].
Gandhi, Neel R. ;
Moll, Anthony ;
Sturm, A. Willem ;
Pawinski, Robert ;
Govender, Thiloshini ;
Lalloo, Umesh ;
Zeller, Kimberly ;
Andrews, Jason ;
Friedland, Gerald .
LANCET, 2006, 368 (9547) :1575-1580
[10]  
Githui WA, 2000, INT J TUBERC LUNG D, V4, P947